SCHEMBL16615940

SCHEMBL16615940

Cc1ncc(CNC(=O)c2cnc(CNS(=O)(=O)c3ccsc3)cn2)s1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2A Q12879 4/20 0.68
GRIN1 Q05586 2/20 0.68
GRIN2B Q13224 1/20 0.52
CASP3 P42574 1/20 0.39
LMNA P02545 4/20 0.36
EDNRA P25101 1/20 0.35
KMT2A Q03164 4/20 0.34
MEN1 O00255 3/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 3/20 0.33
ALDH1A1 P00352 2/20 0.33
PKM P14618 1/20 0.33
CYP1A2 P05177 1/20 0.33
POLB P06746 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
CYP2C19 P33261 1/20 0.33
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16615831 0.86 GRIN2A (0.54) GRIN2AGRIN1GRIN2BEDNRAKMT2A
SCHEMBL16615933 0.85 GRIN2A (0.77) GRIN2AGRIN1GRIN2BCASP3LMNA
SCHEMBL16598350 0.83 GRIN2A (0.77) GRIN2AGRIN1GRIN2BCASP3LMNA
SCHEMBL16598210 0.83 GRIN2A (0.74) GRIN2AGRIN1GRIN2BCASP3KMT2A
SCHEMBL16598003 0.83 GRIN2A (0.85) GRIN2AGRIN1GRIN2BCASP3LMNA
SCHEMBL16598233 0.83 GRIN2A (0.85) GRIN2AGRIN1GRIN2BCASP3LMNA
SCHEMBL16615942 0.83 GRIN2A (0.63) GRIN2AGRIN1GRIN2BKMT2AMEN1
SCHEMBL16615832 0.82 GRIN2A (0.78) GRIN2AGRIN1GRIN2BCASP3LMNA
SCHEMBL16598056 0.81 GRIN2A (0.87) GRIN2AGRIN1GRIN2BCASP3LMNA
SCHEMBL16598054 0.81 GRIN2A (1.00) GRIN2AGRIN1GRIN2BCASP3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US disclosed
WO-2015048503-A2 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. (US) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 GRIN2A 1/4885GRIN1 5/4885GRIN2B 2/4885
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 GRIN2A 1/4885GRIN1 5/4885GRIN2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.